Sedana Medical AB (publ) recruits Chief Medical Officer
Sedana Medical AB (publ), developing and marketing the medical device AnaConda and volatile anesthetics for sedation of mechanically ventilated intensive care unit (ICU) patients, announced the recruitment of Peter Sackey, MD, PhD as Chief Medical Officer (CMO) today.
Peter Sackey has over twenty years’ clinical experience as an anesthesiologist and ICU physician and has been recruited from a position as Senior Consultant and Associate Professor at the Department of Intensive Care Medicine, Perioperative Medicine and Intensive Care, Karolinska University Hospital in Sweden. Peter Sackey is one of the leading researchers in inhalation sedation in the world and was the first to use AnaConDa in intensive care.
Peter Sackey has a strong clinical and scientific background in the field of Intensive Care Medicine and clinical research. After completing his thesis “Isoflurane sedation in ICU patients” he has supervised PhD students in the field of ICU sedation and analgesia as well as ICU follow-up. Peter, who is certified in Intensive Care Medicine (EDIC) has led several clinical trials and multicenter studies and has also been involved in medical product development and has had a central role in Research and Development in Anesthsiology and Intensive Care Medicine for many years.
Peter will start as CMO on 8th January 2018 and will initially focus on Sedana Medical’s primary pharmaceutical drug candidate IsoConDa. The product is in an advanced phase in its clinical development, targeting its use for sedation of critically ill ICU patients. The recruitment of Peter Sackey will accelerate the activities in building an effective organization to support the overall company strategy for the registration and marketing of IsoconDa together with AnaConDa in Europe and the US.
“We are very happy to strengthen our organization with Peter Sackey in this exciting phase of development for Sedana Medical. His extensive clinical and scientific background together with his experience in building and developing strong teams will be a cornerstone in the marketing of IsoConDa together with AnaConda for Intensive Care” says Christer Ahlberg, CEO of Sedana Medical.
The market in brief
Sedana Medical's market consists primarily of mechanically ventilated intensive care patients. The market for sedation of mechanically ventilated intensive care patients today consists of established drugs that are administered intravenously. The target group the Company is focusing on are those patients who are ventilated for more than 24 hours, a target group that globally amounts to between two and four million patients per year. In total, the Company consider this to be a market of SEK 10-20 billion per year, of which Europe accounts for about SEK 6 billion.
For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30, E-mail: Christer.email@example.com
Pareto Securities is certified advisor to Sedana Medical.
Sedana Medical AB (publ) is a Swedish company that develops, manufactures and sells the medical device AnaConDa. AnaConDa is a medical device for inhalation sedation of mechanically ventilated patients in intensive care units. At the end of 2016, the company initiated a major clinical study to receive market approval in Europe for IsoConDa (isoflurane) for inhalation sedation in intensive care units. The study is expected to end in late 2018. Registration is expected at the end of 2019. Sedana Medical has sales offices in Germany, Spain and France, as well as external distributors in Europe, the Middle East, Canada, Australia and South Korea. The headquarters is based in Danderyd, Sweden and the company has R&D operations in Ireland.